Long Islanders suffering from sleep apnea inundated the sleep center at St. Charles Hospital in Port Jefferson with phone ...

Topline results were announced from a second phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in patients with OSA.

Once dismissed as just snoring, sleep apnea is now emerging as an early warning sign for serious conditions like Alzheimer’s, ...

(Reuters) - Eli Lilly's blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk's rival ...

Apnimed's experimental drug reduced breathing interruptions by nearly 46.8% in clinical trials, offering a potential ...

In today’s Health Alert, obstructive sleep apnea may soon be treated with a simple, once-a-day pill. This first-in-class oral ...

Topline results from a second phase 3 trial of AD109-an investigational oral therapy combining aroxybutynin and ...

The first oral pill for obstructive sleep apnea could be around the corner after company Apnimed reported positive results ...

CAMBRIDGE, MA, USA I July 23, 2025 I Apnimed, Inc., a pharmaceutical company advancing an industry-leading pipeline of first-in-class oral therapies that ...

Tens of millions of people in the United States struggle with obstructive sleep apnea, a condition that occurs when the throat muscles narrow during sleep, leading to temporary pauses in breathing ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...